Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $42.61
    +0.04 (+0.09%)

    Market Cap: $51.92B

    Last updated: Nov 17, 2026 at 4:32 PM ET

    Teva Pharma Industries Ltd ADR (TEVA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Teva Pharma Industries Ltd ADR (TEVA) has a market cap of $51.92B and an enterprise value of $64.56B. Its trailing P/E of 14.4x is above its 10-year median of 4.7x.

    Total Valuation

    Enterprise value is 24.33% above the market cap, as debt exceeds cash.

    Market Cap$51.92B
    Enterprise Value$64.56B
    Latest price (Nov 17, 2026)$42.61

    Key Dates

    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.55% in the quarter ended Sep 30, 2026 and grew 2.18% a year over 2 years.

    Shares Outstanding1.18B
    Shares Change (YoY)+1.63%
    Shares Change (QoQ)+1.55%
    Share Count Growth (2Y CAGR)+2.18%

    Valuation Ratios

    Sales and book value multiples are 2.9x and 6.3x. Its year-end P/E ranged from 3.1x to 10.8x from 2016 to 2025.

    P/E Ratio14.4x
    Forward P/E21.0x
    P/S Ratio2.9x
    Forward P/S3.1x
    P/B Ratio6.3x
    P/FCF Ratio40.8x
    P/OCF Ratio29.3x
    PEG Ratio1.5

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 30.9x EBITDA and 51.0x free cash flow.

    EV / Earnings127.6x
    EV / Sales3.7x
    EV / EBITDA30.9x
    EV / EBIT61.2x
    EV / FCF51.0x

    Price Statistics

    The stock is up 67.69% over 52 weeks and trades 5.42% above its 50-day average.

    Beta (1Y)0.61
    52-Week Change+67.69%
    1-Month Change+3.15%
    3-Month Change+13.72%
    6-Month Change+25.07%
    5-Year Change+381.58%
    10-Year Change-1.52%
    Total Return (1Y)+67.69%
    Total Return (3Y CAGR)+67.59%
    Total Return (5Y CAGR)+36.53%
    Return vs SPY (1Y)+59.98%
    Max Drawdown (1Y)-21.79%
    Max Drawdown (3Y)-43.70%
    Sharpe Ratio (1Y)1.62
    Correlation with SPY (1Y)0.25
    50-Day Average$40.42
    200-Day Average$35.18
    52-Week Range$24.01 to $44.57
    RSI (14 Days)55.7
    Average Volume (20 Days)7.37M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.95x current liabilities, and total debt is 2.10x shareholder equity.

    Current Ratio0.95x
    Quick Ratio0.74x
    Debt / Equity2.10x
    Debt / EBITDA8.20x
    Debt / FCF13.53x
    Interest Coverage1.22x

    Returns and Efficiency

    Return on invested capital is 4.27% over the last 12 months, against a 5-year average of 4.65%.

    Return on Equity (ROE)6.34%
    Return on Assets (ROA)1.26%
    Return on Invested Capital (ROIC)4.27%
    Return on Capital Employed (ROCE)4.29%
    ROE (5Y Average)-9.48%
    ROA (5Y Average)-1.34%
    ROIC (5Y Average)4.65%
    Asset Turnover0.43x
    Inventory Turnover2.51x
    Receivables Turnover4.70x
    Cash Conversion Cycle103 days

    Scores

    TEVA has an Altman Z-Score of 0.96, in the distress zone below 1.81, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score0.96
    Altman Z ZoneDistress
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $17.23B over the last 12 months is up 2.70% from the 12 months before.

    Revenue$17.23B
    Revenue Growth (YoY)+2.70%
    Gross Profit$9.22B
    Operating Income$1.44B
    Pretax Income$372.00M
    Net Income$506.00M
    EBITDA$2.04B
    EBIT$1.05B
    Reported EPS (TTM)$2.96

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 19.93% of the $40.04B in total assets.

    Cash and Equivalents$4.08B
    Total Debt$16.72B
    Net Debt$12.63B
    Working Capital-$823.00M
    Shareholder Equity$7.98B
    Tangible Book Value-$11.07B
    Total Assets$40.04B
    Total Liabilities$32.06B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $534.00M of capital spending, operating cash flow left $1.24B of free cash flow.

    Operating Cash Flow$1.77B
    Capital Expenditures$534.00M
    Free Cash Flow$1.24B
    FCF Per Share$1.06
    Depreciation and Amortization$985.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 8.33%, against a 5-year average of 1.90%.

    Gross Margin53.52%
    Operating Margin8.33%
    Pretax Margin2.16%
    Net Margin2.94%
    EBITDA Margin11.84%
    EBIT Margin6.12%
    FCF Margin7.17%
    Gross Margin (5Y Average)48.66%
    Operating Margin (5Y Average)1.90%
    Net Margin (5Y Average)-3.81%

    Growth

    Revenue grew 4.96% a year over 3 years, and EPS 4.53% a year.

    Revenue Growth (3Y CAGR)+4.96%
    Revenue Growth (5Y CAGR)+0.71%
    EPS Growth (3Y CAGR)+4.53%
    EPS Growth (5Y CAGR)+2.37%
    FCF Growth (3Y CAGR)+3.28%
    FCF Growth (5Y CAGR)+12.47%

    Revenue and profit by year

    Dividends and Yields

    TEVA does not pay a dividend. Its free cash flow yield is 2.45%.

    Earnings Yield6.94%
    FCF Yield2.45%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 2-for-1 forward split on Jul 1, 2004.

    Last Split DateJul 1, 2004
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 8 similar companies, TEVA has the 6th highest P/E.

    P/E Ratio14.4x vs 19.9x median
    P/S Ratio2.9x vs 2.3x median
    ROIC4.27% vs 5.65% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.70% vs +7.20% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 2.16% and EPS growth at 7.88% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+2.16%
    EPS Growth Forecast (5Y CAGR)+7.88%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TEVA

    What is TEVA's market cap?

    Teva Pharma Industries Ltd ADR has a market cap of $51.92B. Its enterprise value, which adds debt and subtracts cash, is $64.56B.

    What is TEVA's P/E ratio?

    Teva Pharma Industries Ltd ADR has a trailing P/E ratio of 14.4x and a forward P/E of 21.0x.

    How many shares of TEVA are outstanding?

    Teva Pharma Industries Ltd ADR has 1.18B shares outstanding. The count is up 1.63% from a year earlier.

    Does TEVA pay a dividend?

    No. Teva Pharma Industries Ltd ADR does not pay a dividend.

    How much debt does TEVA have?

    Teva Pharma Industries Ltd ADR has $16.72B of total debt and $4.08B of cash and equivalents, a net debt position of $12.63B.